Table 2.
Crude odds ratio (95% CI) | p valuea | Adjusted odds ratio (95% CI) | p valuea | |
---|---|---|---|---|
Age (continuous) | 1.02 (1.02–1.02) | < .001 | 1.01 (1.01–1.01) | < .001 |
Gender, male | 1.09 (1.08–1.10) | < .001 | 1.02 (1.02–1.03) | < .001 |
Tertiary hospital | 0.94 (0.91–0.97) | < .001 | 1.05 (1.05–1.06) | 0.365 |
Year | 1.02 (1.02–1.02) | < .001 | 1.18 (1.17–1.20) | < .001 |
Charlson index | 1.08 (1.08–1.09) | < .001 | 0.98 (0.95–1.02) | < .001 |
Comorbidity | ||||
Myocardial infarction | 1.00 (0.97–1.02) | 0.857 | 0.85 (0.83–0.87) | < .001 |
Congestive heart failure | 1.50 (1.48–1.53) | < .001 | 1.16 (1.14–1.18) | < .001 |
Peripheral vascular disease | 1.12 (1.15–1.18) | < .001 | 0.94 (0.93–0.96) | < .001 |
Cerebrovascular disease | 0.97 (0.95–0.98) | < .001 | 0.78 (0.77–0.79) | < .001 |
Rheumatologic disease | 1.23 (1.20–1.26) | < .001 | 0.98 (0.96–1.01) | 0.239 |
Peptic ulcer disease | 1.07 (1.06–1.08) | < .001 | 0.88 (0.87–0.89) | < .001 |
Liver disease | 1.28 (1.27–1.30) | < .001 | 0.99 (0.98–1.01) | 0.431 |
Diabetes mellitus | 1.61 (1.60–1.63) | < .001 | 1.26 (1.25–1.28) | < .001 |
Renal disease | 4.23 (4.15–4.32) | < .001 | 3.45 (3.37–3.52) | < .001 |
Cancer | 1.06 (1.05–1.08) | < .001 | 0.72 (0.70–0.74) | < .001 |
AIDS/HIV | 1.46 (1.18–1.81) | < .001 | 0.85 (0.67–1.06) | 0.151 |
Organ dysfunction | ||||
Respiratory | 4.84 (4.75–4.94) | < .001 | 2.97 (2.91–3.04) | < .001 |
Cardiovascular | 5.89 (5.81–5.97) | < .001 | 4.24 (4.18–4.31) | < .001 |
Hepatic | 4.56 (4.33–4.81) | < .001 | 3.46 (3.26–3.67) | < .001 |
Hematologic | 5.24 (5.15–5.33) | < .001 | 3.64 (3.57–3.70) | < .001 |
Neurologic | 2.49 (2.42–2.56) | < .001 | 1.84 (1.78–1.90) | < .001 |
Adjusted for age, gender, tertiary hospital, year, Charlson index, myocardial infarction, congestive heart failure, cerebrovascular disease, rheumatologic disease, peptic ulcer disease, liver disease, diabetes, renal disease, cancer, AIDS/HIV, and organ dysfunction (respiratory, cardiovascular, hepatic, hematologic, neurologic)
AIDS acquired immune deficiency syndrome, CI confidence interval, HIV human immunodeficiency virus
aMixed effects logistic regression model